Hexiris Ophthalmics, a Canadian ophthalmic device company focused on expanding access to interventional glaucoma care, has announced a series of significant milestones as it prepares for the commercial launch of its first products later in 2026. The company presented scientific data at two major international ophthalmology congresses, launched its website and social media channels, and continues to engage surgeons through its educational programs. At the upcoming Canadian Ophthalmological Society (COS) Annual Meeting in Montreal, Quebec, this June, Hexiris will invite surgeons to experience its OBi Core and OBi Gon devices through an in-booth hands-on dry lab.
Scientific Presentations at Major Congresses
In early 2026, Hexiris Ophthalmics presented at the ASCRS Annual Meeting and the Mexican Society of Ophthalmology Meeting. At ASCRS, Dr. Paul Harasymowycz presented data on office-based slit-lamp interventional glaucoma surgery. At the Mexican Society meeting, Dr. José Ramón Ponce Martínez presented clinical experience with the same approach under the title "Cirugía del Glaucoma Intervencional con Lámpara de Hendidura en el Consultorio." These presentations reflect growing interest in moving glaucoma surgery from the operating room to the office setting.
Office-Based Surgery: The Next Frontier in Glaucoma Care
Ophthalmology has been at the forefront of the shift toward office-based surgery. Procedures that once required a hospital operating room are now routinely performed in outpatient and office settings, with outcomes that match or exceed those of traditional surgical environments. Cataract surgery is the clearest example: office-based cataract surgery has been shown to reduce total patient costs by 30 to 50 percent compared with hospital or ambulatory surgery center settings, without any compromise in safety. Surveys suggest that 66 percent of ophthalmologists expect to incorporate office-based surgery into their practice within the next five years.
Glaucoma is widely seen as the next frontier. An estimated 80 million people worldwide live with glaucoma today, a number projected to rise to 111.8 million by 2040. Despite effective surgical treatments, the vast majority of patients who could benefit from intervention never receive it: up to 80 percent of glaucoma cases in developed countries remain undetected or untreated, rising to 90 percent in parts of the developing world. The limiting factor has not been the science but access to care. Glaucoma surgery has historically been confined to the operating room, creating a bottleneck that leaves millions of patients without timely care. The emergence of devices capable of performing effective glaucoma procedures at the slit lamp in a physician's office represents a fundamental shift in what is possible.
Hexiris Ophthalmics' Commitment to Expanding Access
"Expanding access to interventional glaucoma is why Hexiris Ophthalmics exists. Too many patients who need treatment cannot get it, not because the surgery is unavailable, but because the settings in which it can be performed are out of reach. We are building the tools to change that, and we are genuinely excited to be moving closer to putting them in surgeons' hands," said Dr. Houfar Sekhavat, Co-Founder of Hexiris Ophthalmics.
The company's OBi Core and OBi Gon devices are designed for single-vector, bidirectional excisional goniotomy, leveraging the conventional outflow pathway. These micro-invasive glaucoma surgery (MIGS) devices aim to make interventional glaucoma procedures more accessible in office-based settings.
Upcoming COS Annual Meeting Participation
At the COS Annual Meeting in Montreal, Hexiris will offer surgeons the opportunity to participate in a hands-on dry lab, allowing them to experience the OBi Core and OBi Gon devices firsthand. This initiative is part of the company's broader surgeon engagement program, which aims to educate and train ophthalmologists in office-based interventional glaucoma techniques.
With its digital presence now live, Hexiris Ophthalmics is poised to connect with a wider audience of eye care professionals and patients, sharing updates on its progress and the potential of office-based glaucoma surgery to transform patient care.
